STOCK TITAN

Biolinerx - BLRX STOCK NEWS

Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.

BioLineRx Ltd (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company advancing innovative therapies in oncology and rare diseases, including its FDA-approved stem cell mobilizer APHEXDA®. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.

Investors and researchers will find verified updates on pipeline progress, regulatory milestones, and operational initiatives. Content includes earnings reports, clinical data publications, licensing agreements, and manufacturing updates, all sourced directly from BioLineRx communications.

Regularly refreshed with new developments, this resource enables stakeholders to track the company’s work in areas like multiple myeloma treatment optimization and sickle cell disease gene therapy research. Bookmark this page for efficient monitoring of BLRX’s advancements in targeted drug development and commercialization strategies.

Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced the presentation of a poster at the AACR Annual Meeting, detailing a Phase 2a study of motixafortide in combination with KEYTRUDA and chemotherapy for metastatic pancreatic cancer. The study, which evaluated 38 patients, highlighted the challenges faced by patients with liver metastases. Key findings include a median overall survival (mOS) of 6.5 months and an overall response rate (ORR) of 21.1%. The company aims to advance discussions for potential collaborations and anticipates final data from a Phase 3 study in stem cell mobilization soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) reported its financial results for 2020, highlighting positive interim data from its GENESIS Phase 3 trial of motixafortide for stem-cell mobilization, leading to early enrollment cessation. The firm anticipates NDA submission in the first half of 2022. Additionally, the triple combination study of motixafortide with KEYTRUDA and chemotherapy demonstrated improved outcomes in stage IV pancreatic cancer. The year ended with a net loss of $30 million, but the company bolstered its finances with $34.5 million from a public offering, supporting continued development of motixafortide and AGI-134.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) will announce its 2020 financial results on February 23, 2021, before US markets open. A conference call is scheduled for the same day at 10:00 a.m. EST, featuring CEO Philip Serlin. Investors can join via the Investor Relations page. The company's lead program, Motixafortide, focuses on oncology and has undergone successful trials. BioLineRx is also advancing a second program, AGI-134, an immunotherapy for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
conferences
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced the closing of its underwritten offering of 14,375,000 American Depositary Shares (ADSs) at $2.40 each, raising approximately $34.5 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., included the full exercise of their option for an additional 1,875,000 ADSs. Proceeds will support general corporate purposes, including working capital and clinical trials. BioLineRx, focused on oncology, is advancing its lead program Motixafortide and developing AGI-134 for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced an increase in its offering of American Depositary Shares (ADSs) to 12.5 million at $2.40 each due to demand, expecting gross proceeds of around $30 million. The offering is set to close on or about January 22, 2021. The underwriter, H.C. Wainwright & Co., has a 30-day option to purchase an additional 1.875 million ADSs. The proceeds will be used for corporate purposes, including funding clinical trials. The offering follows a previously filed shelf registration with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.71%
Tags
none
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced an underwriting agreement with H.C. Wainwright & Co. for the purchase of 4,166,667 American Depositary Shares (ADSs) at $2.40 each. The offering is expected to close around January 22, 2021, with gross proceeds estimated at $10 million. The funds will be utilized for general corporate purposes, including funding clinical trials. The underwriter also holds a 30-day option to purchase an additional 625,000 ADSs. This offering follows a recently effective shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.71%
Tags
none
Rhea-AI Summary

BioLineRx reported results from the COMBAT/KEYNOTE-202 study on motixafortide (BL-8040) for stage IV pancreatic cancer, showing significant efficacy improvements over historical data. The study involved 43 patients, yielding a median overall survival of 6.5 months (vs. 4.7 months historical) and a confirmed overall response rate of 13.2% (vs. 7.7% historical). The combination was well-tolerated with safety advantages noted, including lower instances of grade 3 neutropenia and infections. The results underscore the potential of motixafortide in improving treatment outcomes for pancreatic ductal adenocarcinoma patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.99%
Tags
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) reported its Q3 2020 financial results, highlighting significant clinical advancements, including a positive interim analysis from the GENESIS Phase 3 trial of motixafortide for stem cell mobilization in multiple myeloma, resulting in a recommendation to cease enrollment at 122 patients. R&D expenses decreased to $3.5 million, a reduction of $2.1 million year-over-year. The net loss for Q3 2020 was $4.6 million, compared to $3.9 million in 2019. BioLineRx held $20.8 million in cash and equivalents as of September 30, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
-
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company specializing in oncology, will announce its unaudited financial results for the quarter ending September 30, 2020, on November 23, 2020, before US markets open. The company will host a conference call at 10:00 a.m. EST on the same day, featuring remarks from CEO Philip Serlin. Interested parties can listen via the Investor Relations page. BioLineRx is leading developments in cancer therapies, including Motixafortide and AGI-134.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) has announced a Phase 1b clinical trial of its lead drug candidate, Motixafortide, aimed at treating acute respiratory distress syndrome (ARDS) related to COVID-19 and other viral infections. The study, led by Dr. Yasmin Maor at Wolfson Medical Center, will enroll up to 25 patients, assessing safety and exploratory respiratory parameters. Preliminary results are expected in the first half of 2021. The company also plans to share full data from its Phase 2a pancreatic cancer study and interim results from its AML study by the end of 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
clinical trial covid-19
Biolinerx

Nasdaq:BLRX

BLRX Rankings

BLRX Stock Data

10.72M
3.55M
4.68%
1.41%
6.44%
Biotechnology
Healthcare
Link
Israel
Hevel Modi'in